(Q42233070)

19 October 2017

title

The theoretical impact and cost-effectiveness of vaccines that protect against sexually transmitted infections and disease (English)

1 reference

sexually transmitted infection

19 October 2017

main subject

0 references

author name string

Geoff P Garnett

series ordinal

1

1 reference

19 October 2017

language of work or name

English

0 references

publication date

1 March 2014

1 reference

19 October 2017

1 reference

19 October 2017

volume

32

1 reference

19 October 2017

issue

14

1 reference

19 October 2017

page(s)

1536-1542

1 reference

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Health and economic implications of HPV vaccination in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Notions of synergy for combinations of interventions against infectious diseases in heterogeneously mixing populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Role of herd immunity in determining the effect of vaccines against sexually transmitted disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Epidemiology and control and curable sexually transmitted diseases: opportunities and problems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Antimicrobial resistance in sexually transmitted infections in the developed world: implications for rational treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Chlamydial infections and the risk of ectopic pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Population-based study of fertility in women with HIV-1 infection in Uganda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Worldwide patterns of infertility: is Africa different?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

How much infertility does chlamydia cause?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Estimation of the impact of genital warts on health-related quality of life.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

The estimated direct medical cost of sexually transmitted diseases among American youth, 2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Productivity losses attributable to untreated chlamydial infection and associated pelvic inflammatory disease in reproductive-aged women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Economic evaluation of vaccination programs: the impact of herd-immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Modelling HIV vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Estimability and Interpretation of Vaccine Efficacy Using Frailty Mixing Models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Estimation of summary protective efficacy using a frailty mixture model for recurrent event time data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

An introduction to mathematical models in sexually transmitted disease epidemiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Imperfect vaccines and herd immunity to HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

The potential epidemiological impact of a genital herpes vaccine for women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Efficacy results of a trial of a herpes simplex vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

The development and use of the concept of a sexually transmitted disease core

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Inequalities in the uptake of human papillomavirus vaccination: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.007

10.1016/J.VACCINE.2013.11.007

7 January 2021

Identifiers

DOI

1 reference

19 October 2017

1 reference